FDA IND clearance permits a U.S. phase 2 registration-oriented trial of FG001 in high-grade glioma, with first-patient-in expected during Q2 2026. Fluorescence-guided surgery with FG001 aims to ...
Please provide your email address to receive an email when new articles are posted on . Frontotemporal dementia is a rare neurodegenerative disorder that worsens over time. Coya Therapeutics is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results